Literature DB >> 21733476

Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk.

Madhukar H Trivedi1, Stephen R Wisniewski, David W Morris, Maurizio Fava, Jackie K Gollan, Diane Warden, Andrew A Nierenberg, Bradley N Gaynes, Mustafa M Husain, James F Luther, Sidney Zisook, A John Rush.   

Abstract

OBJECTIVE: Monitoring suicidality and risk following initiation of antidepressant treatment is an essential component of clinical care, but few brief, reliable ratings of suicidal ideation and behavior in adults are available. This report evaluates the psychometric properties of a brief self- and clinician-rated measure of factors related to the risk of suicide attempt or completion.
METHOD: Adult outpatients with nonpsychotic major depressive disorder (MDD) (n = 240) were enrolled from July 2007 through February 2008 and treated in an 8-week, open-label trial with the clinician's choice of a selective serotonin reuptake inhibitor at 6 primary care and 9 psychiatric clinical care settings in the National Institute of Mental Health-funded Depression Trials Network. Diagnosis of MDD was determined by the Psychiatric Diagnostic Screening Questionnaire and an MDD checklist based on DSM-IV-TR criteria. Suicidal ideation and behavior are 1 of 9 symptoms of MDD (depressed mood, loss of interest, appetite or weight change, sleep disturbance, reduced concentration or indecisiveness, fatigue or decreased energy, psychomotor agitation or retardation, feelings of worthlessness, or excessive guilt). The newly developed Concise Health Risk Tracking (CHRT) scale was administered both as the CHRT Self-Report (CHRT-SR) and Clinician Rating (CHRT-C) scales. Psychometric evaluations were conducted on both scales.
RESULTS: The internal consistency (Cronbach α) was .77 for the 7-item CHRT-C and .78 for the 7-item CHRT-SR with a consistent factor structure, and 3 independent factors (current suicidal thoughts and plans, perceived lack of social support, and hopelessness) for both versions.
CONCLUSIONS: The 7-item CHRT-C and the 7-item CHRT-SR have excellent psychometric properties and can be used to monitor suicidal risk in clinical practice and research settings. Whether either scale will predict suicide attempts or completions in actual practice would require a very large prospective study sample. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT00532103. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733476     DOI: 10.4088/JCP.11m06837

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  41 in total

1.  Measurement-based care for unipolar depression.

Authors:  David W Morris; Madhukar H Trivedi
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

2.  Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study.

Authors:  Laura E Dichtel; Maren Nyer; David Mischoulon; Maurizio Fava; Karen K Miller; Christina Dording; Lauren B Fisher; Cristina Cusin; Benjamin G Shapero; Paola Pedrelli; Allison S Kimball; Elizabeth M Rao
Journal:  J Clin Psychiatry       Date:  2020-06-09       Impact factor: 4.384

3.  A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder.

Authors:  Dawn F Ionescu; Maurizio Fava; Daniel Ju Hyung Kim; Lee Baer; Richard C Shelton; Cristina Cusin
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

4.  A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder.

Authors:  Katherine Sanchez; Michael O Killian; Taryn L Mayes; Tracy L Greer; Joseph M Trombello; Robert Lindblad; Bruce D Grannemann; Thomas J Carmody; A John Rush; Robrina Walker; Madhukar H Trivedi
Journal:  J Psychiatr Res       Date:  2018-03-27       Impact factor: 4.791

5.  Feasible evidence-based strategies to manage depression in primary care.

Authors:  Benji T Kurian; Bruce Grannemann; Madhukar H Trivedi
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

6.  A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR).

Authors:  Michael J Ostacher; Andrew A Nierenberg; Dustin Rabideau; Noreen A Reilly-Harrington; Louisa G Sylvia; Alexandra K Gold; Leah W Shesler; Terence A Ketter; Charles L Bowden; Joseph R Calabrese; Edward S Friedman; Dan V Iosifescu; Michael E Thase; Andrew C Leon; Madhukar H Trivedi
Journal:  J Psychiatr Res       Date:  2015-10-09       Impact factor: 4.791

7.  Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.

Authors:  Sharon C Sung; Stephen R Wisniewski; James F Luther; Madhukar H Trivedi; A John Rush
Journal:  J Affect Disord       Date:  2014-11-22       Impact factor: 4.839

8.  Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders.

Authors:  Diane Warden; Katherine Sanchez; Tracy Greer; Thomas Carmody; Robrina Walker; Adriane Dela Cruz; Marisa Toups; Chad Rethorst; Madhukar H Trivedi
Journal:  Psychiatry Res       Date:  2016-09-15       Impact factor: 3.222

9.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

10.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.